Table 6.
Treatment-related characteristics of COVID-19–positive patients.
| Treatment-related characteristics (n = 113) | |
|---|---|
| Treatment intent | |
| Curative | 40 (35.4%) |
| Palliative | 73 (64.6%) |
| SACT within 6 weeks of admission | 85 |
| Cytotoxic chemotherapy | 58 |
| Tyrosine kinase inhibitors | 11 |
| Other small molecule inhibitors | 1 |
| CDK4-6 inhibitors | 4 |
| PARP inhibitors | 2 |
| Trial | 1 |
| Cytotoxic and CPI | 4 |
| CPI only | 0 |
| Non-CPI monoclonal antibody | 2 |
| Hormone therapy only | 2 |
| Radiotherapy within 6 weeks | 11 (9.7%) |
COVID-19 = coronavirus disease 2019; SACT = systemic anticancer therapy; CPI = checkpoint inhibitor; CDK4/6 = Cyclin-dependent kinase 4 and 6; PARP = Poly(ADP-ribose) polymerase.